---
figid: PMC11955304__MCO2-6-e70152-g003
figtitle: STAT3 signaling pathway can be targeted using various therapeutic agents
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC11955304
filename: MCO2-6-e70152-g003.jpg
figlink: /pmc/articles/PMC11955304/figure/F5/
number: F5
caption: The STAT3 signaling pathway can be targeted using various therapeutic agents.
  Monoclonal antibodies that inhibit IL‐6 include MEDI5117, clazakizumab, olokizumab,
  siltuximab, and sarilumab. Additionally, monoclonal antibodies such as sarilumab
  and tocilizumab block both classical and trans‐signaling pathways of IL‐6R. Olamkicept,
  a fusion protein of gp130 and Fc, selectively inhibits IL‐6 trans‐signaling while
  modulating classical signaling. Tyrosine kinase inhibitors, including tofacitinib,
  ruxolitinib, pacritinib, and AZD1480, are small molecules that target JAKs, preventing
  STAT3 phosphorylation. Other inhibitors, such as those targeting the Src homology
  2 (SH2) domain—C188‐9, OPB‐51602, and OPB‐31121—disrupt STAT3 dimerization. AZD9150,
  an antisense oligonucleotide, binds to and degrades STAT3 mRNA, thereby reducing
  its expression. Additionally, cyclic STAT3 decoy, derived from the FOS target gene
  promoter, competitively inhibits STAT3 binding to genomic response elements in target
  gene promoter regions, thereby suppressing STAT3‐mediated transcription. Created
  with Biorender.com. SHP1, Src homology region 2 (SH2) domain‐containing phosphatase
  1; PP2A, protein phosphatase 2A
papertitle: STAT3 Signaling Pathway in Health and Disease
reftext: Md Abdus Samad, et al. MedComm (2020). 2025 Apr;6(4).
year: '2025'
doi: 10.1002/mco2.70152
journal_title: MedComm
journal_nlm_ta: MedComm (2020)
publisher_name: Wiley
keywords: cancer | IL‐6 pathway | JAK/STAT signaling | nanomaterial‐based drug delivery
  | STAT3 | targeted therapy
automl_pathway: 0.960704
figid_alias: PMC11955304__F5
figtype: Figure
redirect_from: /figures/PMC11955304__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11955304__MCO2-6-e70152-g003.html
  '@type': Dataset
  description: The STAT3 signaling pathway can be targeted using various therapeutic
    agents. Monoclonal antibodies that inhibit IL‐6 include MEDI5117, clazakizumab,
    olokizumab, siltuximab, and sarilumab. Additionally, monoclonal antibodies such
    as sarilumab and tocilizumab block both classical and trans‐signaling pathways
    of IL‐6R. Olamkicept, a fusion protein of gp130 and Fc, selectively inhibits IL‐6
    trans‐signaling while modulating classical signaling. Tyrosine kinase inhibitors,
    including tofacitinib, ruxolitinib, pacritinib, and AZD1480, are small molecules
    that target JAKs, preventing STAT3 phosphorylation. Other inhibitors, such as
    those targeting the Src homology 2 (SH2) domain—C188‐9, OPB‐51602, and OPB‐31121—disrupt
    STAT3 dimerization. AZD9150, an antisense oligonucleotide, binds to and degrades
    STAT3 mRNA, thereby reducing its expression. Additionally, cyclic STAT3 decoy,
    derived from the FOS target gene promoter, competitively inhibits STAT3 binding
    to genomic response elements in target gene promoter regions, thereby suppressing
    STAT3‐mediated transcription. Created with Biorender.com. SHP1, Src homology region
    2 (SH2) domain‐containing phosphatase 1; PP2A, protein phosphatase 2A
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - il6st
  - il6
  - vegfaa
  - egf
  - celsr1a
  - il6r
  - kita
  - ngfra
  - src
  - stat3
  - ptpn6
  - cpa1
  - IL6ST
  - NM
  - LRPPRC
  - IL6
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - IL6R
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - HMGA2
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SRC
  - FGR
  - FYN
  - YES1
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - GNAS
  - GNAL
  - GNAQ
  - GNA11
  - GNA14
  - GNA15
  - GNA12
  - GNA13
  - STAT3
  - PTPN6
  - NR0B2
  - CPA1
  - PTPA
  - CYP2A7
  - hormones
  - Ruxolitinib
  - BGJ398
  - Bosutinib
  - Pacritinib
  - Dasatinib
  - KX2-391
  - Ponatinib
  - SB1518
  - S31-201
  - Agonist
  - inhibitors
  - LYS
  - Nucleus
---
